NASDAQ:ATHE Alterity Therapeutics (ATHE) Stock Price, News & Analysis $5.40 +0.09 (+1.69%) Closing price 08/8/2025 03:59 PM EasternExtended Trading$5.38 -0.02 (-0.37%) As of 08/8/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Alterity Therapeutics Stock (NASDAQ:ATHE) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Alterity Therapeutics alerts:Sign Up Key Stats Today's Range$5.17▼$5.5650-Day Range$3.84▼$6.5552-Week Range$1.00▼$7.00Volume36,738 shsAverage Volume177,767 shsMarket Capitalization$47.90 millionP/E RatioN/ADividend YieldN/APrice Target$12.00Consensus RatingModerate Buy Company Overview Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434 that is in Phase I clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; ATH434-202 that is in Phase II clinical trial to treat multiple system atrophy advance; and PBT2 that has completed Phase 2a clinical trial to treat Alzheimer's disease. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is headquartered in Melbourne, Australia. Read More Alterity Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks34th Percentile Overall ScoreATHE MarketRank™: Alterity Therapeutics scored higher than 34% of companies evaluated by MarketBeat, and ranked 746th out of 925 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.3 / 5Analyst RatingModerate Buy Consensus RatingAlterity Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.Amount of Analyst CoverageAlterity Therapeutics has received no research coverage in the past 90 days.Read more about Alterity Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Book Value per Share RatioAlterity Therapeutics has a P/B Ratio of 5.19. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.06% of the float of Alterity Therapeutics has been sold short.Short Interest Ratio / Days to CoverAlterity Therapeutics has a short interest ratio ("days to cover") of 2.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Alterity Therapeutics has recently increased by 20.33%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAlterity Therapeutics does not currently pay a dividend.Dividend GrowthAlterity Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted1.06% of the float of Alterity Therapeutics has been sold short.Short Interest Ratio / Days to CoverAlterity Therapeutics has a short interest ratio ("days to cover") of 2.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Alterity Therapeutics has recently increased by 20.33%, indicating that investor sentiment is decreasing significantly. News and Social Media1.1 / 5News SentimentN/A Search Interest1 people have searched for ATHE on MarketBeat in the last 30 days. MarketBeat Follows1 people have added Alterity Therapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Alterity Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders38.80% of the stock of Alterity Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 2.14% of the stock of Alterity Therapeutics is held by institutions.Read more about Alterity Therapeutics' insider trading history. Receive ATHE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Alterity Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address ATHE Stock News HeadlinesAppendix 4C – Q4 FY25 Quarterly Cash Flow ReportJuly 30, 2025 | globenewswire.comAlterity Therapeutics Reports Positive Topline Data from Open-Label Phase 2 Clinical Trial of ATH434 in Multiple System AtrophyJuly 28, 2025 | globenewswire.comAmericans are rushing into gold (but not billionaires!)Billionaires Are Piling into a Special Gold Investment With record gold prices, everyday Americans are scrambling to buy gold coins and bars. But some savvy investors have used a different way to profit from gold bull runs — a special investment with a long history of making 13 times … 21 times … 157 times … even a surprising 1,000 times more than physical gold.August 10 at 2:00 AM | Weiss Ratings (Ad)Alterity Therapeutics Ltd. ADR (ATHE) Stock Price Today - WSJJuly 26, 2025 | wsj.comAlterity Therapeutics Announces Publication on Novel MRI Endpoint from the bioMUSE Natural History StudyJuly 24, 2025 | globenewswire.comAlterity Therapeutics to Provide Corporate Update in Fireside ChatJune 23, 2025 | globenewswire.comAlterity Therapeutics highlighted at MSA CongressMay 14, 2025 | uk.investing.comAlterity Therapeutics Prominently Featured at the International MSA CongressMay 12, 2025 | globenewswire.comSee More Headlines ATHE Stock Analysis - Frequently Asked Questions How have ATHE shares performed this year? Alterity Therapeutics' stock was trading at $3.31 at the start of the year. Since then, ATHE shares have increased by 63.1% and is now trading at $5.40. When did Alterity Therapeutics' stock split? Alterity Therapeutics shares reverse split on the morning of Monday, January 9th 2023.The 1-10 reverse split was announced on Monday, January 9th 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, January 9th 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. Who are Alterity Therapeutics' major shareholders? Top institutional investors of Alterity Therapeutics include Greenleaf Trust (0.19%). How do I buy shares of Alterity Therapeutics? Shares of ATHE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Alterity Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Alterity Therapeutics investors own include NVIDIA (NVDA), GE Aerospace (GE), Broadcom (AVGO), Meta Platforms (META), Dorian LPG (LPG), CymaBay Therapeutics (CBAY) and Company Calendar Today8/10/2025Fiscal Year End6/30/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ATHE CIK1131343 Webwww.alteritytherapeutics.com Phone(139) 349-4906Fax61-3-9348-0377Employees10Year FoundedN/APrice Target and Rating Average Price Target for Alterity Therapeutics$12.00 High Price Target$12.00 Low Price Target$12.00 Potential Upside/Downside+122.2%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage2 Analysts Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio3.84 Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.04 per share Price / Book5.19Miscellaneous Outstanding Shares8,870,000Free Float5,427,000Market Cap$47.90 million OptionableNot Optionable Beta0.67 Social Links A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for August 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free Report This page (NASDAQ:ATHE) was last updated on 8/10/2025 by MarketBeat.com Staff From Our PartnersI trusted Trump and got screwedPorter Stansberry says he got one thing wrong—and now millions of Americans could pay the price. After warning...Porter & Company | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredAltucher: Trump’s Great Gain is startingNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredMarket Crash Warning: How to Protect Your Wealth Before August 12thChina tariffs hit August 12—and experts warn a market meltdown may follow. A free guide from American Alter...American Alternative | SponsoredBut this $20 American company could control the secretThe "Impossible" Chip That Runs on Pure Light Google's quantum computer shocked the world... but China DEMO...The Oxford Club | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThe stealth altcoin the financial world is underestimatingThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alterity Therapeutics Limited - Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Alterity Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.